AU2004266443A1 - Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline - Google Patents

Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline Download PDF

Info

Publication number
AU2004266443A1
AU2004266443A1 AU2004266443A AU2004266443A AU2004266443A1 AU 2004266443 A1 AU2004266443 A1 AU 2004266443A1 AU 2004266443 A AU2004266443 A AU 2004266443A AU 2004266443 A AU2004266443 A AU 2004266443A AU 2004266443 A1 AU2004266443 A1 AU 2004266443A1
Authority
AU
Australia
Prior art keywords
zinc
weight
present
solution according
aqueous pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004266443A
Other languages
English (en)
Inventor
Frank Bohme
Bernd Eschenbach
Dagmar Farber
Claudia Hey
Barbara Pfaff
Marion Tschaikin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004266443(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2004266443A1 publication Critical patent/AU2004266443A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2004266443A 2003-08-13 2004-07-14 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline Abandoned AU2004266443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10337186.9 2003-08-13
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
PCT/EP2004/007780 WO2005018601A1 (de) 2003-08-13 2004-07-14 Wässrige phramateuziche lösung enthaltend oxymetazolin und/oder xylometazolin

Publications (1)

Publication Number Publication Date
AU2004266443A1 true AU2004266443A1 (en) 2005-03-03

Family

ID=34201503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004266443A Abandoned AU2004266443A1 (en) 2003-08-13 2004-07-14 Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline

Country Status (19)

Country Link
US (1) US20060222718A1 (https=)
EP (1) EP1663141B1 (https=)
JP (1) JP4750703B2 (https=)
KR (1) KR20060065677A (https=)
CN (1) CN100531733C (https=)
AT (1) ATE357212T1 (https=)
AU (1) AU2004266443A1 (https=)
BR (1) BRPI0413478A (https=)
CA (1) CA2535533C (https=)
CY (1) CY1107633T1 (https=)
DE (2) DE10337186A1 (https=)
DK (1) DK1663141T3 (https=)
ES (1) ES2282871T3 (https=)
MX (1) MXPA06001596A (https=)
PL (1) PL1663141T3 (https=)
PT (1) PT1663141E (https=)
RU (1) RU2343918C2 (https=)
WO (1) WO2005018601A1 (https=)
ZA (1) ZA200602071B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE102007052380A1 (de) † 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101576539B (zh) * 2009-06-19 2012-05-23 广东省药品检验所 一种盐酸赛洛唑啉中杂质a的测定方法
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
DE102012005452A1 (de) * 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US20170348230A1 (en) 2014-12-24 2017-12-07 Jadran-Galenski Laboratorij D.D A nasal composition containing sea water as stability-improving excipient
BR112018072177A2 (pt) * 2016-05-17 2019-02-12 Proponent Biotech Gmbh composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
DE202017104738U1 (de) 2017-07-31 2018-08-01 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
CN107362141B (zh) * 2017-08-16 2018-06-05 深圳大佛药业股份有限公司 一种盐酸羟甲唑啉鼻喷雾剂及其制备方法
US20210244710A1 (en) * 2018-07-02 2021-08-12 Kangping Xiao Stable pharmaceutical formulations of oxymetazoline
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
WO2023046590A1 (en) 2021-09-22 2023-03-30 Jadran - Galenski Laboratorij D.D. An improved pharmaceutical composition for nasal use, preparation, and use thereof
CN117982422B (zh) * 2024-04-03 2024-07-26 深圳大佛药业股份有限公司 一种用于治疗鼻炎的喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
CA2311530C (en) * 1998-01-30 2008-06-10 Novartis Consumer Health S.A. Nasal solutions
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
NL1011016C2 (nl) * 1999-01-13 2000-07-14 Dagra Pharma Bv Neusspray op basis van xylometazoline en kamille-extract.
AU765736B2 (en) * 1999-06-22 2003-09-25 Boehringer Ingelheim International Gmbh Stable xylometazoline and oxymetazoline solution
EP1328214A4 (en) * 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
RU2212235C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Капли назальные бризолин, обладающие сосудосуживающим, противовоспалительным и противоотечным действием

Also Published As

Publication number Publication date
JP4750703B2 (ja) 2011-08-17
ATE357212T1 (de) 2007-04-15
RU2006107446A (ru) 2007-09-20
CN100531733C (zh) 2009-08-26
WO2005018601A1 (de) 2005-03-03
DK1663141T3 (da) 2007-07-30
PT1663141E (pt) 2007-06-27
ZA200602071B (en) 2007-05-30
BRPI0413478A (pt) 2006-10-17
EP1663141A1 (de) 2006-06-07
JP2007501817A (ja) 2007-02-01
MXPA06001596A (es) 2006-05-19
RU2343918C2 (ru) 2009-01-20
CA2535533A1 (en) 2005-03-03
KR20060065677A (ko) 2006-06-14
CY1107633T1 (el) 2013-03-13
DE10337186A1 (de) 2005-03-17
PL1663141T3 (pl) 2007-07-31
EP1663141B1 (de) 2007-03-21
DE502004003305D1 (de) 2007-05-03
US20060222718A1 (en) 2006-10-05
CN1832726A (zh) 2006-09-13
CA2535533C (en) 2011-10-18
ES2282871T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
AU2004266443A1 (en) Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline
JP3090125B2 (ja) ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
US4153689A (en) Stable insulin preparation for nasal administration
DE69108200T2 (de) 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1).
NL192563C (nl) Vloeibaar farmaceutisch preparaat voor toediening via de neus dat een in de natuur voorkomend calcitonine bevat.
AU8856998A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
JPH01153639A (ja) 鼻又は目に使用する薬剤及びその製造法
JP6349057B2 (ja) オロパタジン含有水性組成物
US6368616B1 (en) Aqueous suspension for nasal administration of loteprednol
TWI845795B (zh) 眼用醫藥組合物
JP2003128537A (ja) 安定化された組成物
JP2003055258A (ja) 安定化された組成物
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.
EP1297838B1 (en) Pralmorelin-containing nasal drop preparations
CN101756964A (zh) 一种含有盐酸赛洛唑啉的复方药用鼻腔喷雾剂
JP2003055224A (ja) 安定化された組成物
HUT63060A (en) Process for producing pharmaceutical compositions locally applicable on nose and eye, comprising bradykinin antagonists
JPH10259132A (ja) 点鼻用水性懸濁液
JP2005239691A (ja) トラニラスト含有医薬組成物
RU2611659C1 (ru) Фармацевтическая композиция в виде назального спрея на основе кеторолака и способ ее получения
RU2443416C2 (ru) Капли глазные
JP2025016743A (ja) オロパタジン含有水性組成物
JP2025516407A (ja) Ｖｖｎ００１含有眼科組成物
BG65674B1 (bg) Течна форма на комбинирано лекарствено средство за лечение на простудни и грипни заболявания
CZ13722U1 (cs) Oční instilace se zlepšenou stabilitou účinné látky na bázi brimonidinu

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted